GILEAD SCIENCES, INC. Deferred Tax Assets, Capital Loss Carryforwards
GILEAD SCIENCES, INC. (GILD) had Deferred Tax Assets, Capital Loss Carryforwards of $187.00 million as of 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsCapitalLossCarryforwards · last filed 2026-02-24
- 2025-12-31: Deferred Tax Assets, Capital Loss Carryforwards $187.00M.
- 2024-12-31: Deferred Tax Assets, Capital Loss Carryforwards $590.00M.
- 2023-12-31: Deferred Tax Assets, Capital Loss Carryforwards $17.00M.
| Period end | Deferred Tax Assets, Capital Loss Carryforwards |
|---|---|
| 2025-12-31 | $187.00M 10-K · filed 2026-02-24 |
| 2024-12-31 | $590.00M 10-K · filed 2026-02-24 |
| 2023-12-31 | $17.00M 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |